Key Points {#FPar1}
==========

Although the prevalence and presentation of atopic dermatitis (AD) vary by race and ethnicity, existing treatment guidelines do not provide specific recommendations for treating patients with skin of color.Crisaborole improved global disease severity in patients aged ≥ 2 years with mild-to-moderate AD across races and ethnicities, with a low frequency of treatment-related adverse events.No adverse events related to skin discoloration were reported with crisaborole treatment in nonwhite and Hispanic/Latino patients, and crisaborole improved AD signs/symptoms common in these populations, including induration/papulation and lichenification.

Introduction {#Sec1}
============

Atopic dermatitis (AD) is a common inflammatory skin disorder that often follows a chronic relapsing course \[[@CR1], [@CR2]\]. AD is characterized by inflamed eczematous lesions and intense pruritus \[[@CR2]\]. Mounting evidence suggests that AD epidemiology, etiology, and presentation vary across racial and ethnic groups. National surveys as well as smaller studies conducted in US general pediatric and pediatric dermatology clinics have reported a higher AD prevalence in children who are black/African American \[[@CR3]--[@CR5]\], Asian \[[@CR5], [@CR6]\], and Hispanic \[[@CR5]\] compared with white/not Hispanic children. Global trends provide further evidence of racial/ethnic disparities, as phase III of the International Study of Asthma and Allergies in Childhood (ISAAC) reported wide global variation in eczema prevalence, with prevalence rates for children aged 6--7 years ranging from 0.9% (Jodhpur, India) to 22.5% (Quito, Ecuador) \[[@CR7]\]. Disease burden may be higher in patients with skin of color, as black/African American and Asian children are more likely than white children to visit a doctor for a diagnosis of AD \[[@CR5], [@CR8]\]. Patients with skin of color may also progress to greater disease severity before diagnosis as a result of racial and ethnic variations in presentation and difficulty in discerning AD signs, such as erythema \[[@CR9], [@CR10]\]. Disease presentation varies by race and ethnicity in that the dermatitic lesions of patients with skin of color are more likely to be follicular based, papular, or lichenoid, and resolved lesions tend to show dyschromia/altered pigmentation \[[@CR9], [@CR11]\]. Compared with those of European Americans, lesions of East Asian individuals are more likely to be psoriasiform and to show clear demarcation, lichenification, and scaling \[[@CR12], [@CR13]\]. African Americans are more likely than other racial groups to present with prurigo nodularis, lichenification, scattered follicular papules on the extensors and trunk, and lichen planus-like AD \[[@CR9], [@CR13]\].

Immune mechanisms may contribute to ethnic and racial variation in AD presentation. Compared with AD lesions of European Americans, lesions of East Asian individuals show a greater induction of T-helper (Th) 17 and Th22 cytokines \[[@CR12]\], and lesions of African Americans show reduced activation of Th1 and Th17 axes \[[@CR14]\]. Other hypothesized racial immune differences include higher serum immunoglobulin E levels and larger mast cell granule size in black/African American patients compared with white patients \[[@CR9], [@CR14]--[@CR16]\].

Despite noted racial and ethnic differences in disease presentation and immune profile, patients with skin of color are underrepresented in clinical trials for AD, and race and ethnicity are often not considered in the interpretation of findings \[[@CR17]\]. Reflecting these patterns, treatment guidelines do not provide specific information for treating patients with skin of color \[[@CR18]--[@CR20]\]. As AD is more prevalent in patients with skin of color, racial and ethnic subgroup analyses of clinical trial data are of particular importance \[[@CR17]\].

Crisaborole ointment is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of mild-to-moderate AD \[[@CR21]\]. Inhibition of phosphodiesterase 4 by crisaborole increases levels of 3′5′-cyclic adenosine monophosphate in inflammatory cells, leading to activation of nuclear factor κB and nuclear factor of activated T-cell signaling pathways and subsequent suppression of inflammatory cytokine release. Two identically designed, pivotal phase III trials investigating the safety and efficacy of crisaborole ointment, 2%, for patients with mild-to-moderate AD found that more crisaborole-treated patients than vehicle-treated patients achieved improvement in global disease severity and signs and symptoms of AD, including pruritus \[[@CR22]\]. Most treatment-emergent adverse events (TEAEs) were mild-to-moderate and considered unrelated to treatment. Long-term safety analysis for crisaborole from the two pivotal studies and a 48-week safety extension study showed a low frequency of treatment-related adverse events (AEs) (10.3%), of which the most frequently reported were AD \[3.1%; worsening, exacerbation, flare, or flare-up of existing condition, classified by the Medical Dictionary for Regulatory Activities (MedDRA) as dermatitis atopic\], application site pain (2.3%), and application site infection (1.2%) \[[@CR23]\].

The objective of this pooled post hoc analysis of the pivotal studies and long-term safety study was to investigate the efficacy and safety of crisaborole ointment, 2%, for the treatment of mild-to-moderate AD in patients aged ≥ 2 years according to race and ethnicity.

Methods {#Sec2}
=======

Study Design and Oversight {#Sec3}
--------------------------

A pooled post hoc analysis of two identically designed, multicenter, randomized, vehicle-controlled, double-blind, pivotal phase III studies (ClinicalTrials.gov AD-301: NCT02118766; AD-302: NCT02118792) and an open-label, 48-week, long-term safety study (AD-303) was conducted. Full details of the phase III and long-term safety studies have been reported previously \[[@CR22], [@CR23]\].

Patients {#Sec4}
--------

In the two pivotal studies (AD-301, AD-302), patients were randomly assigned 2:1 to receive crisaborole ointment or vehicle. Key inclusion criteria required patients to be aged ≥ 2 years, have a clinical diagnosis of AD according to Hanifin and Rajka criteria, have an Investigator's Static Global Assessment (ISGA) score of mild (2) or moderate (3) at baseline, and have ≥ 5% treatable body surface area involvement (excluding the scalp). At selected investigator sites, patients completing pivotal study AD-301 or AD-302 without experiencing a treatment-related AE or serious AE that prompted crisaborole discontinuation were eligible for enrollment in the long-term safety extension study (AD-303) within 8 days of the end of the study visit.

Crisaborole or Vehicle Treatment {#Sec5}
--------------------------------

In the two pivotal studies (AD-301, AD-302), patients were instructed to apply a thin layer of study drug ointment (crisaborole or vehicle) twice daily for 28 days to all treatable AD-involved areas (excluding the scalp) identified at baseline/day 1 and to any new lesions appearing after day 1. In the long-term extension study (AD-303), patient global disease severity was assessed every 28 days for 48 weeks using the ISGA, a 5-point static scale indicating clear (0), almost clear (1), mild (2), moderate (3), or severe (4) disease. Patients with ISGA scores ≥ 2 entered or continued an additional 28-day on-treatment period of twice-daily crisaborole application. Patients with ISGA scores ≤ 1 entered or continued an additional off-treatment period during which no study drug was applied. Crisaborole ointment treatment was discontinued in patients who showed no improvement in ISGA score after three consecutive on-treatment periods. The maximum number of consecutive treatment cycles was 3. In all three trials, the use of bland emollient(s) to manage dry skin was permitted on uninvolved skin but prohibited on AD-involved skin.

Efficacy Assessments (AD-301, AD-302) {#Sec6}
-------------------------------------

Global disease severity was assessed at baseline and on days 8, 15, 22, and 29 using the ISGA scale. The primary efficacy endpoint was the proportion of patients achieving success in ISGA at day 29 in the crisaborole-treated group compared with the vehicle-treated group. Success in ISGA was defined as an ISGA score of clear (0) or almost clear (1) with a ≥ 2-grade improvement from baseline. The secondary efficacy endpoints were the proportion of patients with ISGA scores of clear (0) or almost clear (1) at day 29 and time to ISGA success. Additional efficacy endpoints included improvements in pruritus, signs of AD, and quality of life (QoL). Pruritus was measured twice daily by an electronic diary using the Severity of Pruritus (SPS) scale, a 4-point scale indicating none (0), mild (1), moderate (2), or severe (3) pruritus. Baseline pruritus severity was calculated as the average of two or more assessments on day 1. Weekly SPS scores were calculated for each patient as the average of all available post-baseline SPS scores during the corresponding week (generally up to 14 measurements). Signs of AD (erythema, induration/papulation, exudation, excoriation, and lichenification) were evaluated at baseline and on days 8, 15, 22, and 29 using a 4-point scale from none (0) to severe (3). Improvement in pruritus or AD signs was defined as a score of none (0) or mild (1) with a ≥ 1-grade improvement from baseline. QoL assessments were made at baseline and at day 29 using age-appropriate questionnaires \[Children's Dermatology Life Quality Index (CDLQI) for patients aged 2--15 years; Dermatology Life Quality Index (DLQI) for patients aged ≥ 16 years; Dermatology Family Impact Questionnaire (DFI) for parents/caregivers/families of patients aged 2--17 years\]. All QoL assessments were made on a scale of 0--30 points, with higher scores indicating poorer QoL. In study AD-303, there were no pre-defined efficacy analyses, as this was an open-label, long-term, safety extension study.

Safety Assessments (AD-301, AD-302, AD-303) {#Sec7}
-------------------------------------------

Frequencies of AEs and serious AEs (SAEs) were assessed at baseline, at scheduled and unscheduled investigator visits, and at study conclusion in the pivotal studies (AD-301, AD-302). Frequencies of AEs and SAEs and local tolerability were assessed on the first day of each 28-day treatment cycle and at study conclusion for the long-term extension study (AD-303). AEs were recorded and classified using MedDRA terminology. TEAEs were defined as AEs with an onset on or after the day of the first study drug dose. Treatment-related TEAEs were events determined by the study investigator to be definitely, probably, or possibly related to treatment.

Post Hoc Statistical Analysis {#Sec8}
-----------------------------

Efficacy and safety endpoints were assessed by racial and ethnic group. For statistical analyses, the designated racial categories were white and nonwhite, with the nonwhite group encompassing the following racial subgroups: Asian/native Hawaiian/other Pacific Islander, black/African American, and other/American Indian/Alaskan native. Designated ethnic categories were Hispanic/Latino and not Hispanic/Latino. Efficacy analyses were performed on the intention-to-treat (ITT) population, defined as all patients who were randomly assigned and dispensed the study drug. For ISGA, the difference between treatment groups in the proportions of patients achieving predefined improvement or successful outcomes was calculated at days 8, 15, 22, and 29. Time to ISGA success was plotted using Kaplan--Meier methods. For signs of AD at day 29, the difference between treatment groups in the proportion of patients achieving improvement was calculated. For QoL scores at day 29, the difference between treatment groups in the least-squares mean change from baseline was calculated. Post hoc analysis of the difference in the proportion of patients achieving improvement in pruritus at weeks 1, 2, 3, and 4 was performed as described previously \[[@CR24]\]. Statistical significance was set at a nominal 0.05 level. Nonwhite subgroups (Asian/native Hawaiian/other Pacific Islander, black/African American, and other/American Indian/Alaskan native) were small and were therefore pooled to improve reliability of statistical analyses. *p* values for the nonwhite subgroups are provided for informational purposes, but interpretation of these values is limited by the small sample size. The safety population consisted of all patients who were randomized, received one or more confirmed doses of the study drug, and had one or more post-baseline assessments. For safety endpoints in the pivotal (AD-301 and AD-302) and long-term extension (AD-303) studies, frequencies of TEAEs, serious TEAEs, and treatment-related TEAEs were summarized. Long-term safety data include AEs reported throughout the pivotal studies (AD-301 and AD-302, 4 weeks) and the long-term safety study (AD-303, 48 weeks) for a total of 52 weeks among patients who enrolled in study AD-303.

Results {#Sec9}
=======

Patients and Enrollment {#Sec10}
-----------------------

The ITT population of the pivotal studies (AD-301 and AD-302) included a total of 1522 patients assigned 1016:506 to receive crisaborole:vehicle \[Table [1](#Tab1){ref-type="table"}, white (*N* = 923), nonwhite (*N* = 599), Hispanic/Latino (*N* = 301), not Hispanic/Latino (*N* = 1221)\]. Baseline demographics and disease characteristics were similar across treatment and race/ethnicity groups. The proportion of patients with mild (ISGA 2, 34.7--40.1%) or moderate (ISGA 3, 59.9--65.3%) AD at baseline was similar across race, ethnicity, and treatment groups, and the majority of patients had moderate (average SPS 1.5 to \< 2.5, 31.0--36.63%) and severe (average SPS 2.5 to ≤ 3, 19.0--21.8%) pruritus at baseline. Within the nonwhite group, 424 patients (70.8%) were black/African American, 94 patients (15.7%) were Asian/native Hawaiian/other Pacific Islander, and 81 patients (13.5%) were other/American Indian/Alaskan native \[see Table 1 of the Electronic Supplementary Material (ESM) for baseline demographics and disease characteristics of nonwhite racial subgroups\].Table 1Baseline demographics and disease characteristics \[AD-301 and AD-302 intention-to-treat (ITT) population\]WhiteNonwhiteHispanic/LatinoNot Hispanic/LatinoCrisaborole *N* = 617Vehicle *N* = 306Crisaborole *N* = 399Vehicle *N* = 200Crisaborole *N *= 200Vehicle *N* = 101Crisaborole *N* = 816Vehicle *N* = 405Age, mean (range), years12.3 (2--79)11.2 (2--79)12.3 (2--64)13.4 (2--72)10.5 (2--59)9.2 (2--41)12.8 (2--79)12.8 (2--79)Age group, %, years 2--1162.263.760.960.063.068.361.460.7 12--1724.625.523.823.028.023.823.424.7 ≥ 1813.110.815.317.09.07.915.214.6Female, %51.751.661.961.552.060.456.654.3ISGA, % Mild: 237.837.640.139.037.034.739.139.0 Moderate: 362.262.459.961.063.065.360.961.0Average SPS score, % None: 0 to \< 0.51.621.631.251.002.502.971.230.99 Mild: 0.5 to \< 1.517.9918.9518.0523.0017.5017.8218.1421.23 Moderate: 1.5 to \< 2.536.6332.6831.5831.0036.0033.6634.3131.60 Severe: 2.5 to ≤ 320.5819.6121.8019.0021.0020.7921.0819.01The ITT population was defined as all patients who were randomly assigned and dispensed the study drug*ISGA* Investigator's Static Global Assessment, *SPS* severity of pruritus

Efficacy Endpoints {#Sec11}
------------------

More crisaborole-treated patients than vehicle-treated patients achieved success in ISGA on days 8, 15, 22, and 29 (the primary efficacy endpoint) across race and ethnicity (AD-301 and AD-302, nominal *p* \< 0.05 for all racial and ethnic groups and time points) (Fig. [1](#Fig1){ref-type="fig"}a, b). The proportion of patients achieving success in ISGA at day 29 in crisaborole-treated vs. vehicle-treated patients in nonwhite racial subgroups was 20.6% vs. 14.2% (Asian/native Hawaiian/other Pacific Islander, nominal *p* = 0.4524), 32.1% vs. 24.6% (black/African American, nominal *p *= 0.1349), and 29.1% vs. 13.2% (other/American Indian/Alaskan native, nominal *p* = 0.0923). Shorter time to ISGA success with crisaborole vs. vehicle was observed in white, nonwhite, Hispanic/Latino, and not Hispanic/Latino groups, and a similar pattern was observed for nonwhite racial subgroups (Figs. 1, 2 of the ESM).Fig. 1Improvement in global disease severity: Investigator's Static Global Assessment (ISGA) success (AD-301 and AD-302, intention-to-treat \[ITT\] population). **a** Proportion of patients who achieved success in ISGA by ethnicity and race. Data are shown as mean ± standard error of the mean. **b** Difference in the proportion of patients who achieved success in ISGA at day 29 by ethnicity and race. Data are shown as mean difference ± 95% confidence interval. Nominal \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001, \*\*\*\**p* \< 0.0001

More crisaborole-treated than vehicle-treated patients also achieved ISGA scores of clear or almost clear at all time points in all racial and ethnic groups (nominal *p* \< 0.05, Fig. [2](#Fig2){ref-type="fig"}a, b). Proportions of patients achieving clear or almost clear ISGA scores at day 29 in nonwhite racial subgroups (crisaborole vs. vehicle) was 33.8% vs. 28.5% (Asian/native Hawaiian/other Pacific Islander, nominal *p* = 0.6152), 49.7% vs. 33.7% (black/African American, nominal *p *\< 0.01), and 54.9% vs. 34.5% (other/American Indian/Alaskan native, nominal *p* = 0.0904).Fig. 2Improvement in global disease severity: Investigator's Static Global Assessment (ISGA) score of clear or almost clear (AD-301 and AD-302, intention-to-treat \[ITT\] population). **a** Proportion of patients who achieved an ISGA score of clear (0) or almost clear (1) by ethnicity and race. Data are shown as mean ± standard error of the mean. **b** Difference in the proportion of patients who achieved an ISGA score of clear (0) or almost clear (1) at day 29 by ethnicity and race. Data are shown as mean difference ± 95% confidence interval. Nominal \**p *\< 0.05, \*\**p *\< 0.01, \*\*\**p *\< 0.001, \*\*\*\**p *\< 0.0001

A greater proportion of crisaborole-treated patients than vehicle-treated patients achieved improvement in pruritus at weeks 1, 2, 3, and 4 for all racial and ethnic groups (nominal *p* \< 0.05, Fig. [3](#Fig3){ref-type="fig"}a). Proportions of patients achieving improvement in pruritus at week 4 in nonwhite racial subgroups (crisaborole vs. vehicle) was 28.6% vs. 9.5% (Asian/native Hawaiian/other Pacific Islander, nominal *p* \< 0.05), 33.5% vs. 24.7% (black/African American, nominal *p *= 0.1199), and 32.6% vs. 15.0% (other/American Indian/Alaskan native, nominal *p* = 0.1013).Fig. 3Improvement in pruritus and atopic dermatitis (AD) signs by race and ethnicity (pooled data, AD-301 and AD-302; intention-to-treat \[ITT\] population with an average baseline of two or more assessments \[pruritus\]; ITT population with baseline score \> 0, observed cases \[AD signs\]). **a** Percentage of patients who achieved an improvement in pruritus by race and ethnicity. Data are shown as mean ± standard error of the mean. *N* at day 29 for crisaborole:vehicle was 453:201 (white), 273:134 (nonwhite), 149:66 (Hispanic/Latino), 577:269 (not Hispanic/Latino). **b** Percentage of patients who achieved improvement in AD signs by race and ethnicity at day 29. Data are shown as mean + standard error of the mean. *N* at day 29 for crisaborole:vehicle was erythema (584:272 \[white\], 361:171 \[nonwhite\], 189:87 \[Hispanic/Latino\], 756:356 \[not Hispanic/Latino\]), induration/papulation (579:270 \[white\], 370:178 \[nonwhite\], 189:87 \[Hispanic/Latino\], 760:361 \[not Hispanic/Latino\]), exudation (315:134 \[white\], 195:80 \[nonwhite\], 102:37 \[Hispanic/Latino\], 408:177 \[not Hispanic/Latino\]), excoriation (541:254 \[white\], 344:164 \[nonwhite\], 177:85 \[Hispanic/Latino\], 708:333 \[not Hispanic/Latino\]), and lichenification (535:242 \[white\], 360:171 \[nonwhite\], 180:85 \[Hispanic/Latino\], 715:328 \[not Hispanic/Latino\]). Nominal \**p *\< 0.05, \*\**p *\< 0.01, \*\*\**p *\< 0.001, \*\*\*\**p *\< 0.0001. ^a^For each week, only patients with average baseline and post-baseline assessments were included in the pruritus analysis

At day 29, more crisaborole- than vehicle-treated patients achieved improvement in most AD signs across race and ethnicity groups (Fig. [3](#Fig3){ref-type="fig"}b). A significant difference (nominal *p* \< 0.05) in proportions of patients with improvement in erythema, excoriation, and lichenification at day 29 in crisaborole-treated vs. vehicle-treated patients was observed in all race and ethnicity groups. More crisaborole-treated than vehicle-treated patients demonstrated improvement in lichenification, an AD sign often observed in patients with skin of color, at days 8 and 15 in all groups (nominal *p* \< 0.05, Table 2 of the ESM). Proportions of patients achieving improvement in lichenification remained greater through day 29 in the white, Hispanic/Latino, and not Hispanic/Latino groups (nominal *p* \< 0.05) and was numerically greater in the nonwhite group through day 29 (nominal *p* \< 0.06). Table 3 of the ESM reports data for nonwhite racial subgroups at all in-clinic visits.

Overall, crisaborole-treated patients showed greater improvements in QoL than did vehicle-treated patients across race and ethnicity groups (Fig. [4](#Fig4){ref-type="fig"}). Crisaborole-treated patients aged 2--15 years exhibited a greater reduction in CDLQI score than vehicle-treated patients at day 29 in all race and ethnicity groups (nominal *p* \< 0.01). Crisaborole-treated patients aged ≥ 16 years showed a greater reduction in DLQI score than vehicle-treated patients at day 29 in the nonwhite, Hispanic/Latino, and not Hispanic/Latino groups (nominal *p* \< 0.05, Fig. [4](#Fig4){ref-type="fig"}), although no difference was observed for the white group (nominal *p* = 0.3948). Parents/caregivers/families of crisaborole-treated patients aged 2--17 years showed a greater reduction in DFI score than families of vehicle-treated patients at day 29 in the white, nonwhite, and not Hispanic/Latino groups (nominal *p* \< 0.05, Fig. [4](#Fig4){ref-type="fig"}), although no difference was observed for the Hispanic/Latino group (nominal *p* = 0.2227). Table 4 of the ESM reports CDLQI, DLQI, and DFI data for nonwhite racial subgroups at day 29.Fig. 4Improvement in quality of life (QoL) of patients and parents/caregivers at day 29, assessed as the least-squares mean change from baseline (pooled data, AD-301 and AD-302, intention-to-treat \[ITT\] population). Least-squares mean difference from baseline in QoL score by race and ethnicity. Data are shown as mean -- standard error of the mean. The number of patients achieving an improvement in QoL for each scale is listed in a table below each graph. *CDLQI* Children's Dermatology Life Quality Index, *DLQI* Dermatology Life Quality Index, *DFI* Dermatology Family Impact Questionnaire, nominal \**p *\< 0.05, \*\**p *\< 0.01, \*\*\**p *\< 0.001, \*\*\*\**p *\< 0.0001

Safety Endpoints {#Sec12}
----------------

### Studies AD-301 and AD-302 {#Sec13}

The safety population of the pivotal studies included a total of 1511 patients (Table [2](#Tab2){ref-type="table"}). TEAEs (all causalities) were reported in 27.2--35.1% of crisaborole-treated patients and 25.0--34.3% of vehicle-treated patients across race and ethnicity. The majority of treatment-related TEAEs were mild or moderate. The most frequently reported treatment-related TEAE for all race and ethnicity groups was application site pain (crisaborole vs. vehicle): white \[4.9% (*n* = 30) vs. 1.3% (*n* = 4)\], nonwhite \[3.8% (*n* = 15) vs. 1.0% (*n* = 2)\], Hispanic/Latino \[6.0% (*n* = 12) vs. 2.0% (*n* = 2)\], not Hispanic/Latino \[4.1% (*n* = 33) vs. 1.0% (*n* = 4)\]. One case of mild application site discoloration (hyperpigmentation) was reported in a white, not Hispanic/Latino crisaborole-treated patient. Rates of drug discontinuations due to TEAEs were similar across treatments and racial and ethnic groups (crisaborole vs. vehicle): white \[1.0% (*n* = 6) vs. 2.0% (*n* = 6)\]; nonwhite \[1.8% (*n* = 7) vs. 0.5% (*n* = 1)\], Hispanic/Latino \[1.0% (*n* = 2) vs. 1.0% (*n* = 1)\], not Hispanic/Latino \[1.4% (*n* = 11) vs. 1.5% (*n* = 6)\].Table 2Treatment-emergent adverse events (TEAEs) by race and ethnicity (pooled data, AD-301 and AD-302, safety population)Frequency of TEAEs, *n* (%)WhiteNonwhiteHispanic/LatinoNot Hispanic/LatinoCrisaborole *N* = 615Vehicle *N* = 303Crisaborole *N* = 397Vehicle *N* = 196Crisaborole *N* = 199Vehicle *N* = 99Crisaborole *N* = 813Vehicle *N* = 400≥ 1 TEAE216 (35.1)96 (31.7)108 (27.2)49 (25.0)67 (33.7)34 (34.3)260 (32.0)111 (27.8)≥ 1 serious TEAE4 (0.7)1 (0.3)4 (1.0)03 (1.5)1 (1.0)5 (0.6)0Any treatment-related TEAE44 (7.2)19 (6.3)31 (7.8)6 (3.1)17 (8.5)8 (8.1)58 (7.1)17 (4.3)Treatment-related TEAEs Mild19 (3.1)7 (2.3)13 (3.3)3 (1.5)10 (5.0)2 (2.0)22 (2.7)8 (2.0) Moderate18 (2.9)9 (3.0)14 (3.5)3 (1.5)5 (2.5)5 (5.1)27 (3.3)7 (1.8) Severe7 (1.1)3 (1.0)4 (1.0)02 (1.0)1 (1.0)9 (1.1)2 (0.5)The safety population was defined as all patients who were randomized, received ≥ 1 confirmed dose of the study drug, and had ≥ 1 post-baseline assessment

As in the combined nonwhite group, application site pain was the most frequent treatment-related TEAE in nonwhite subgroups (crisaborole vs. vehicle): Asian/native Hawaiian/other Pacific Islander \[3.4% (*n* = 2) vs. 2.9% (*n* = 1)\]; black/African American \[2.8% (*n* = 8) vs. 0% (*n* = 0)\]; and other/American Indian/Alaskan native \[9.1% (*n* = 5) vs. 4.0% (*n* = 1)\]. Frequencies of TEAEs, serious TEAEs, treatment-related TEAEs, and drug discontinuations due to TEAEs in these subgroups are reported in Table 5 of the ESM.

### Study AD-303 {#Sec14}

Following completion of the pivotal studies, 517 patients enrolled in the long-term safety study (Table [3](#Tab3){ref-type="table"}). TEAEs (all causalities, across pivotal and extension studies) were reported in 54.0--71.7% of crisaborole-treated patients across races and ethnicities. The majority of treatment-related TEAEs were mild or moderate. The most frequently reported treatment-related TEAEs in white and nonwhite patients were AD \[white: 3.2% (*n* = 10); nonwhite: 3.0% (*n* = 6)\] and application site pain \[white: 2.9% (*n* = 9); nonwhite: 1.5% (*n* = 3)\]. AD events involved worsening, exacerbation, flare, or flare-up of existing AD. The most frequently reported treatment-related TEAEs in Hispanic/Latino patients were AD \[7.3% (*n* = 6)\] and application site infection \[2.4% (*n* = 2)\]. In not Hispanic/Latino patients, application site pain \[2.5% (*n* = 11)\] and AD \[2.3% (*n* = 10)\] were most frequently reported. Mean duration of application site pain in patients enrolled in the long-term safety study was 8.3 days (white, *n* = 10), 26.0 days (nonwhite, *n* = 2), 1.0 days (Hispanic/Latino, *n* = 1), and 12.2 days (not Hispanic/Latino, *n* = 11). The proportion of application site pain events that resolved within 1 day was 40.0% (white, 4/10), 0% (nonwhite, 0/2), 100.0% (Hispanic/Latino, 1/1), and 27.3% (not Hispanic/Latino, 3/11). Rates of drug discontinuations due to TEAEs were similar across race and ethnicity groups: white \[1.6% (*n* = 5)\], nonwhite \[2.0% (*n* = 4)\], Hispanic/Latino \[3.7% (*n* = 3)\], not Hispanic/Latino \[1.4% (*n* = 6)\]. Application site pain was the reason for discontinuation in two not Hispanic/Latino patients (0.5%), one white patient (0.3%), and one nonwhite patient (0.5%).Table 3Treatment-emergent adverse events (TEAEs) by race and ethnicity (AD-303, safety population)Frequency of TEAEs, *n* (%)WhiteNonwhiteHispanic/LatinoNot Hispanic/Latino*N* = 315*N* = 202*N* = 82*N* = 435≥ 1 TEAE226 (71.7)109 (54.0)57 (69.5)279 (64.1)≥ 1 serious TEAE3 (1.0)6 (3.0)2 (2.4)7 (1.6)Any treatment-related TEAE33 (10.5)20 (9.9)12 (14.6)41 (9.4)Treatment-related TEAEs Mild13 (4.1)6 (3.0)3 (3.7)16 (3.7) Moderate16 (5.1)11 (5.4)6 (7.3)21 (4.8) Severe4 (1.3)3 (1.5)3 (3.7)4 (0.9)TEAEs were those with an onset on or after the day of the first study drug (crisaborole ointment, 2%, or vehicle) application in AD-301 or AD-302; includes all TEAEs with an onset on or after the day of the first study drug application (crisaborole or vehicle) in AD-301 or AD-302; the safety population was defined as all patients who were randomized, received ≥ 1 confirmed dose of study drug, and had ≥ 1 post-baseline assessment

Frequency of TEAEs, serious TEAEs, treatment-related TEAEs, and drug discontinuations due to TEAEs in nonwhite racial subgroups in the long-term safety extension study are reported in Table 6 of the ESM. As in the combined nonwhite group, AD was the most frequently reported treatment-related TEAE in Asian/native Hawaiian/other Pacific Islander patients (3.4%, *n* = 1), black/African American patients (2.0%, *n* = 3), and other/American Indian/Alaskan native patients (9.5%, *n* = 2). Application site pain was reported in two black/African American patients (1.3%) and one other/American Indian/Alaskan native patient (4.8%). Application site infection was reported in two black/African American patients (1.3%).

Discussion {#Sec15}
==========

This pooled post hoc analysis evaluated the safety and efficacy of crisaborole according to race and ethnicity. We found that crisaborole was efficacious for the treatment of patients aged ≥ 2 years with mild-to-moderate AD regardless of racial or ethnic group. The safety profile of crisaborole was consistent across races and ethnicities, with a low frequency of treatment-related TEAEs in the pivotal and long-term safety extension studies.

The efficacy of crisaborole in decreasing disease severity and improving AD signs and QoL across all racial and ethnic groups indicates that it may have the potential to lessen the burden of disease in patients with skin of color. Available data suggest a higher burden of AD in patients with skin of color. An analysis of two national ambulatory care databases found that black and Asian children were two to three times more likely to visit a physician or hospital for a diagnosis of AD than white children during the survey period (1997--2004) \[[@CR5]\]. An earlier study reported a similar pattern in ambulatory care visits, finding that despite lower overall healthcare utilization, black and Asian/Pacific Islander children were three to seven times more likely to visit a physician for AD than white children during the survey period (1990--8) \[[@CR8]\]. A study in UK children with AD found that while white and black children evaluated with the SCORing AD (SCORAD) index initially showed no difference in disease severity, when erythema was excluded from severity scores, black children were nearly six times more likely to have severe AD than white children \[[@CR10]\]. An increased likelihood of severe AD has consequences for disease burden, as AD severity is correlated with a greater number of chronic health conditions, poorer overall health, higher degree of sleep impairment, and greater use of health services \[[@CR25]\]. In the present study, we observed improvements in global disease severity and pruritus across all racial and ethnic groups. Crisaborole improved AD signs that are common in patients with skin of color, including induration/papulation (improved by crisaborole in nonwhite patients) and lichenification (improved by crisaborole in nonwhite and Hispanic/Latino patients). Significant differences vs. vehicle in the proportions of patients achieving improvement in lichenification were observed at all time points in Hispanic/Latino patients and at three of the four time points in nonwhite patients.

The safety profile of crisaborole suggests that it may be an appropriate treatment option for patients with skin of color. Hyperpigmentation is a concerning AE in patients with skin of color, who are more likely to experience dyspigmentation in healed AD lesions \[[@CR9], [@CR13]\]. While the risk of AEs can be reduced through selection of appropriate topical corticosteroid potency and treatment duration \[[@CR18], [@CR26]\], long-term topical corticosteroid use may be associated with dyspigmentation and skin atrophy, including bruising and striae \[[@CR27]--[@CR29]\]. In these phase III studies of crisaborole, mild treatment-related application site discoloration was reported in one white, not Hispanic/Latino crisaborole-treated patient who experienced gray skin discoloration of hands and feet at the application site. A larger difference from the vehicle in rates of treatment-related TEAEs was observed in nonwhite and not Hispanic/Latino groups compared with the white and Hispanic/Latino groups in the pivotal trials (AD-301 and AD-302); however, this difference was largely driven by a reduction in the rate of treatment-related TEAEs among vehicle-treated patients in nonwhite and not Hispanic/Latino groups. The difference in vehicle-related TEAEs may reflect differences in dermal reaction to vehicle components, the smaller sample size of the vehicle group resulting from the 2:1 randomization scheme, or limitations of the post hoc analysis. Nevertheless, prospective clinical trials are needed to further assess the efficacy and safety of topical therapies in patients with AD by race and ethnicity.

There are limitations to this study. As this was a post hoc analysis and therefore not powered for subgroup comparison, interpretation of the significance of results should not be based on nominal *p* values alone, especially for comparisons of nonwhite racial subgroups because of the small sample size. Furthermore, the present study did not assess skin tone using standardized methods, such as Fitzpatrick scoring, potentially leading to inconsistency in the reporting of race or ethnicity in some patients.

Conclusions {#Sec16}
===========

Regardless of race or ethnicity, crisaborole improved global disease severity in patients aged ≥ 2 years with mild-to-moderate AD. Crisaborole was efficacious in reducing AD signs common in patients with skin of color and was associated with a low frequency of treatment-related TEAEs, suggesting that crisaborole may be an appropriate treatment option for these patients.
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